Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.
1. The efficacy and acceptability of enalapril were assessed in a double-blind, randomised, placebo controlled cross-over study in 21 patients with primary Raynaud's phenomenon. 2. Skin temperature was assessed by thermocouples in response to a 15 degrees C cold water challenge as an index of digital blood flow. 3. Following enalapril there were no significant changes in the number and severity of Raynaud's attacks, and no subjective benefit from treatment as measured by visual analogue scales, 5 point rating scales, and skin temperature response to cold challenge when compared with placebo. 4. Enalapril in a dose of 20 mg daily is ineffective in the management of primary Raynaud's phenomenon.
Challenor
V F
VF
Institute of Sound and Vibration Research, Southampton General Hospital.
Waller
D G
DG
Hayward
R A
RA
Griffin
M J
MJ
Roath
O S
OS
D000328:Adult; D001831:Body Temperature / Q000187:drug effects; D003080:Cold Temperature; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy*
D004656:Enalapril